SA517381298B1 - تركيبة صيدلية بثبات محسن - Google Patents

تركيبة صيدلية بثبات محسن

Info

Publication number
SA517381298B1
SA517381298B1 SA517381298A SA517381298A SA517381298B1 SA 517381298 B1 SA517381298 B1 SA 517381298B1 SA 517381298 A SA517381298 A SA 517381298A SA 517381298 A SA517381298 A SA 517381298A SA 517381298 B1 SA517381298 B1 SA 517381298B1
Authority
SA
Saudi Arabia
Prior art keywords
lactate
conjugate
pharmaceutical composition
based polymer
less
Prior art date
Application number
SA517381298A
Other languages
English (en)
Inventor
جي جوارينو أندرو
لي يوهو
Original Assignee
جي جوارينو أندرو
فورسي فارماسوتيكالز كو ليميتد
لي يوهو
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جي جوارينو أندرو, فورسي فارماسوتيكالز كو ليميتد, لي يوهو filed Critical جي جوارينو أندرو
Publication of SA517381298B1 publication Critical patent/SA517381298B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يوفر الاختراع الحالي تركيبة قابلة للحقن لتوصيل عقار بإطلاق مقنن وعملية لتكوينها، حيث تشتمل التركيبة على: بوليمر أساسه اللاكتات lactate-based polymer له وزن جزيئي حسب متوسط الوزن يتراوح بين 5000 و50000 دالتونdalton ، عدد حمض أقل من 3 مجم KOH/ جم ومحتوى مونومرات لاكتيد متبقية residual lactide monomers في البوليمر الذي أساسه اللاكتات أقل من نحو 0.3% بالوزن؛ مذيب عضوي مقبول صيدليًا؛ ومادة نشطة حيويًا أو ملح منها تحتوي على سيرين حمض أميني amino acid serine في بنية جزيئية قادرة على التفاعل مع مونومر لاكتيد لتكوين مترافق؛ وحيث تقلل التركيبة تكوين المترافق. [الشكل 25]
SA517381298A 2014-10-15 2017-04-12 تركيبة صيدلية بثبات محسن SA517381298B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064008P 2014-10-15 2014-10-15
PCT/US2015/055634 WO2016061296A1 (en) 2014-10-15 2015-10-15 Pharmaceutical composition with improved stability

Publications (1)

Publication Number Publication Date
SA517381298B1 true SA517381298B1 (ar) 2021-12-18

Family

ID=55747307

Family Applications (1)

Application Number Title Priority Date Filing Date
SA517381298A SA517381298B1 (ar) 2014-10-15 2017-04-12 تركيبة صيدلية بثبات محسن

Country Status (19)

Country Link
US (2) US20160106804A1 (ar)
EP (1) EP3207149B1 (ar)
JP (2) JP6717839B2 (ar)
KR (2) KR102134873B1 (ar)
CN (2) CN113209009B (ar)
AU (2) AU2015332456A1 (ar)
BR (1) BR112017007669A2 (ar)
CA (1) CA2964475C (ar)
ES (1) ES2949827T3 (ar)
HR (1) HRP20230716T1 (ar)
HU (1) HUE062326T2 (ar)
IL (1) IL251703B (ar)
MX (2) MX2017005235A (ar)
PL (1) PL3207149T3 (ar)
RS (1) RS64339B1 (ar)
RU (1) RU2728786C2 (ar)
SA (1) SA517381298B1 (ar)
SG (1) SG11201702535QA (ar)
WO (1) WO2016061296A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
EP3565852A1 (en) * 2017-01-04 2019-11-13 Pharmathen S.A. Process for preparing biodegradable polymers of high molecular weight
US20200282008A1 (en) * 2017-01-31 2020-09-10 Veru Inc. COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
CA3052157A1 (en) * 2017-01-31 2018-08-09 Veru Inc. Compositions and methods for long term release of ganadotropin-releasing hormone (gnrh) antagonists
CA3084339A1 (en) * 2017-12-18 2019-06-27 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions having a selected release duration
EP4380546A1 (en) 2021-08-05 2024-06-12 MedinCell S.A. Pharmaceutical composition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3708916A1 (de) 1987-03-19 1988-09-29 Boehringer Ingelheim Kg Verfahren zur reinigung resorbierbarer polyester
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2040141C (en) 1990-04-13 2002-05-14 Minoru Yamada Biodegradable high-molecular polymers, production and use therof
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0572675B1 (en) 1991-12-19 1999-09-22 Mitsui Chemicals, Inc. Polyhydroxy carboxylic acid and production thereof
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
FR2776516B1 (fr) * 1998-03-25 2001-05-25 Pharma Biotech Compositions presentant une liberation prolongee et leur procede de preparation
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
WO2000035990A1 (fr) 1998-12-15 2000-06-22 Takeda Chemical Industries, Ltd. Procede de production d'un polymere
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2819769C (en) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
DK1824460T3 (en) 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
WO2008008363A1 (en) * 2006-07-11 2008-01-17 Qps, Llc Pharmaceutical compositions for sustained release delivery of peptides
FI3660073T3 (fi) * 2007-02-15 2023-09-11 Tolmar International Ltd Matalan purskeen poly(laktidi-ko-glykolidi)
EP2219620B1 (en) * 2007-11-13 2017-07-19 Surmodics, Inc. Viscous terpolymers as drug delivery platform
CA2735581C (en) 2008-08-29 2017-05-30 Genzyme Corporation Controlled-released peptide formulations
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
SG11201702535QA (en) 2017-04-27
KR102134873B1 (ko) 2020-07-17
CN113209009A (zh) 2021-08-06
MX2017005235A (es) 2019-12-11
EP3207149A1 (en) 2017-08-23
JP6928695B2 (ja) 2021-09-01
RS64339B1 (sr) 2023-08-31
KR102274420B1 (ko) 2021-07-08
US20160106804A1 (en) 2016-04-21
NZ730538A (en) 2024-01-26
RU2017111079A (ru) 2018-11-15
PL3207149T3 (pl) 2023-08-21
HUE062326T2 (hu) 2023-10-28
CN107075541A (zh) 2017-08-18
IL251703A0 (en) 2017-06-29
AU2015332456A1 (en) 2017-04-13
JP6717839B2 (ja) 2020-07-08
CN113209009B (zh) 2024-08-20
KR20170070176A (ko) 2017-06-21
ES2949827T3 (es) 2023-10-03
RU2017111079A3 (ar) 2019-05-17
HRP20230716T1 (hr) 2023-10-13
MX2022003939A (es) 2022-04-25
BR112017007669A2 (pt) 2017-12-19
EP3207149A4 (en) 2018-06-13
EP3207149C0 (en) 2023-06-07
AU2019279929B2 (en) 2021-02-25
CA2964475C (en) 2020-03-24
JP2017531697A (ja) 2017-10-26
JP2020147595A (ja) 2020-09-17
CA2964475A1 (en) 2016-04-21
RU2728786C2 (ru) 2020-07-31
CN107075541B (zh) 2021-06-25
IL251703B (en) 2021-03-25
WO2016061296A1 (en) 2016-04-21
US20220160817A1 (en) 2022-05-26
EP3207149B1 (en) 2023-06-07
KR20190029783A (ko) 2019-03-20
AU2019279929A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
MX2023006541A (es) Formulaciones de dosis fija.
RS53205B (en) IMPLANTABLE PALIPERIDON FORMULATION
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
PH12014502668B1 (en) Paliperidone implant formulation
RS54024B1 (en) GASTRORETENCY FORMULATION OF MEDICINES AND SYSTEMS FOR DELIVERY AND METHODS OF THEIR PREPARATION USING FUNCTIONALIZED CALCIUM CARBONATE
EA033537B1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
JP2015517488A5 (ar)
NZ703321A (en) Risperidone or paliperidone implant formulation
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
MX2018005206A (es) Composicion farmaceutica que comprende fibras obtenidas electrohidrodinamicamente y que tiene tiempo de residencia mejorado en el sitio de aplicacion.
SG194175A1 (en) Polymer conjugated prostaglandin analogues
MX2019000381A (es) Formulacion para la administracion de arn.
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
NZ727834A (en) Fast acting orally disintegrating film
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
WO2016008401A8 (zh) 一种含多西他赛的药物组合物
WO2012010938A3 (en) Pharmaceutical composition of cefditoren pivoxil
MX2017001900A (es) Composicion nasal con capacidades de formacion de pelicula.
WO2016055111A8 (en) Amphiphilic copolymers their preparation and use for the delivery of drugs
NZ730538B2 (en) Pharmaceutical composition with improved stability
MX2017016978A (es) Composicion farmaceutica de heparinas de bajo peso molecular.
UA111566C2 (uk) Фармацевтична композиція пролонгованого вивільнення морфолінію [(5-метил-1н-1,2,4-триазол-3-іл)тіо]ацетату